0001193805-21-000657 | 10-Q | XBRL Viewer

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2021	May 07, 2021
Document Information Line Items
Entity Registrant Name	ADMA BIOLOGICS, INC.
Entity Central Index Key	0001368514
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Entity Common Stock Shares Outstanding		128,189,628
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Entity File Number	001-36728
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	56-2590442
Entity Address Address Line 1	465 State Route 17
Entity Address City Or Town	Ramsey
Entity Address State Or Province	NJ
Entity Address Postal Zip Code	07446
City Area Code	201
Local Phone Number	478-5552
PreferredStockMember
Document Information Line Items
Security 12b Title	Preferred Share Purchase Right
Security Exchange Name	NASDAQ
Common Stock
Document Information Line Items
Security 12b Title	Common Stock
Trading Symbol	ADMA
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 61,965,709	$ 55,921,152
Accounts receivable, net	15,362,030	13,237,290
Inventories	94,146,200	81,535,599
Prepaid expenses and other current assets	5,802,608	3,046,466
Total current assets	177,276,547	153,740,507
Property and equipment, net	44,175,613	41,593,090
Intangible assets, net	2,265,283	2,444,121
Goodwill	3,529,509	3,529,509
Right to use assets	6,197,295	4,259,191
Deposits and other assets	2,222,781	2,106,976
TOTAL ASSETS	235,667,028	207,673,394
Current liabilities:
Accounts payable	12,152,852	11,073,708
Accrued expenses and other current liabilities	8,592,142	8,365,143
Current portion of deferred revenue	142,834	142,834
Current portion of lease obligations	317,910	365,682
Total current liabilities	21,205,738	19,947,367
Senior notes payable, net of discount	93,412,660	92,968,866
Deferred revenue, net of current portion	2,082,990	2,118,698
Lease obligations, net of current portion	6,419,589	4,334,151
Other non-current liabilities	41,965	54,886
TOTAL LIABILITIES	123,162,942	119,423,968
STOCKHOLDERS' EQUITY
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock - voting, $0.0001 par value, 150,000,000 shares authorized, 123,044,981 and 104,902,888 shares issued and outstanding	12,304	10,490
Additional paid-in capital	471,336,826	428,704,039
Accumulated deficit	(358,845,044)	(340,465,103)
TOTAL STOCKHOLDERS' EQUITY	112,504,086	88,249,426
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 235,667,028	$ 207,673,394

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
STOCKHOLDERS' EQUITY
Preferred stock, shares par value	$ 0.0001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	123,044,981	104,902,888
Common stock, shares outstanding	123,044,981	104,902,888

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
REVENUES:
Product revenue	$ 16,012,910	$ 10,164,036
License revenue	35,708	35,708
Total revenues	16,048,618	10,199,744
OPERATING EXPENSES:
Cost of product revenue (exclusive of amortization expense shown below)	17,770,122	16,829,226
Research and development	987,649	1,528,738
Plasma center operating expenses	2,242,343	500,644
Amortization of intangible assets	178,838	178,838
Selling, general and administrative	10,033,915	7,932,084
Total operating expenses	31,212,867	26,969,530
LOSS FROM OPERATIONS	(15,164,249)	(16,769,786)
OTHER INCOME (EXPENSE):
Interest income	22,059	248,068
Interest expense	3,195,750	2,717,091
Other expense	(42,001)	(6,421)
Other expense, net	(3,215,692)	(2,475,444)
NET LOSS	$ (18,379,941)	$ (19,245,230)
BASIC AND DILUTED LOSS PER COMMON SHARE	$ (0.16)	$ (0.26)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic and Diluted	115,661,937	73,781,507

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Dec. 31, 2019		59,318,355
Balance, amount at Dec. 31, 2019	$ 26,193,149	$ 5,932	$ 290,903,772	$ (264,716,555)
Stock-based compensation	676,548	$ 0	676,548	0
Issuance of common stock, net of offering expenses, shares		27,025,000
Issuance of common stock, net of offering expenses, amount	88,704,039	$ 2,703	88,701,336	0
Exercise of stock options, shares		1,958
Exercise of stock options, amount	7,177	$ 0	7,177	0
Net loss	(19,245,230)	$ 0	0	(19,245,230)
Stock-based compensation	676,548
Balance, shares at Mar. 31, 2020		86,345,313
Balance, amount at Mar. 31, 2020	96,335,683	$ 8,635	380,288,833	(283,961,785)
Balance, shares at Dec. 31, 2020		104,902,888
Balance, amount at Dec. 31, 2020	88,249,426	$ 10,490	428,704,039	(340,465,103)
Issuance of common stock, net of offering expenses, shares		18,080,708
Issuance of common stock, net of offering expenses, amount	41,912,515	$ 1,808	41,910,707	0
Net loss	(18,379,941)	0	0	(18,379,941)
Stock-based compensation	781,397	$ 0	781,397	0
Vesting of Restricted Stock Units, net of shares withheld for taxes and retired, shares		61,385
Vesting of Restricted Stock Units, net of shares withheld for taxes and retired, amount	(59,311)	$ 6	(59,317)	0
Balance, shares at Mar. 31, 2021		123,044,981
Balance, amount at Mar. 31, 2021	$ 112,504,086	$ 12,304	$ 471,336,826	$ (358,845,044)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (18,379,941)	$ (19,245,230)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,229,628	788,838
Loss on disposal of fixed assets	781	976
Stock-based compensation	781,397	676,548
Amortization of debt discount	443,794	429,711
Amortization of license revenue	(35,708)	(35,708)
Changes in operating assets and liabilities:
Accounts receivable	(2,124,740)	(3,637,915)
Inventories	(12,610,601)	775,932
Prepaid expenses and other current assets	(2,756,142)	(2,321,751)
Deposits and other assets	19,718	(79,532)
Accounts payable	1,079,144	(22,356)
Accrued expenses	(843,043)	(1,930,591)
Other current and non-current liabilities	(33,413)	(45,882)
Net cash used in operating activities	(33,229,126)	(24,646,960)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(2,571,161)	(2,074,876)
Proceeds from the sale of property and equipment	0	2,000
Net cash used in investing activities	(2,571,161)	(2,072,876)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of offering expenses	41,912,515	88,704,039
Proceeds from the exercise of stock options	0	7,177
Taxes paid on vested Restricted Stock Units	(59,311)
Proceeds from issuance of note payable	0	12,500,000
Payments on finance lease obligations	(8,360)	(7,816)
Net cash provided by financing activities	41,844,844	101,203,400
Net increase in cash and cash equivalents	6,044,557	74,483,564
Cash and cash equivalents - beginning of period	55,921,152	26,752,135
Cash and cash equivalents - end of period	$ 61,965,709	$ 101,235,699

ORGANIZATION AND BUSINESS

3 Months Ended

Mar. 31, 2021

ORGANIZATION AND BUSINESS

1. ORGANIZATION AND BUSINESS

1. ORGANIZATION AND BUSINESS

ADMA Biologics, Inc. (“ADMA” or the “Company”) is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.

ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (“ADMA BioManufacturing”) and ADMA BioCenters Georgia Inc. (“ADMA BioCenters”). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of the Biotest Therapy Business Unit (“BTBU”) from BPC Plasma, Inc. (formerly Biotest Pharmaceuticals Corporation) (“BPC” and, together with Biotest AG, “Biotest”) on June 6, 2017. The acquisition included certain assets (the “Biotest Assets”) of BTBU, which included the FDA-licensed BIVIGAM and Nabi-HB immunoglobulin products, and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the “Boca Facility”) (the “Biotest Transaction”). BTBU had previously been the Company’s third-party contract manufacturer. ADMA BioCenters is the Company’s source plasma collection business with seven plasma collection facilities in various stages of approval and development located throughout the U.S., two of which hold an approved license with the U.S. Food and Drug Administration (the “FDA”) while a third facility’s Biologics License Applications (“BLA”) is pending FDA approval.

The Company has three FDA-approved products, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (“IVIG”) product indicated for the treatment of Primary Humoral Immunodeficiency (“PI”), also known as Primary Immunodeficiency Disease (“PIDD”), and for which the Company received FDA approval on May 9, 2019 and commenced commercial sales in August 2019; (ii) ASCENIV (Immune Globulin Intravenous, Human – slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which the Company received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (“HBsAg”) and other listed exposures to Hepatitis B. In addition to its commercially available immunoglobulin products, the Company provides contract manufacturing and laboratory services for certain clients and generates revenues from the sale of intermediate by-products that result from the immunoglobulin production process. The Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.

As of March 31, 2021, the Company had working capital of $156.1 million, including $62.0 million of cash and cash equivalents. Based upon the Company’s current projected revenue and expenditures, including capital expenditures and continued implementation of the Company’s commercialization and expansion activities, as well as accessing the available funds under the open market sale agreement for sales of the Company’s common stock as discussed below, the Company’s management currently believes that its cash, cash equivalents, projected revenue and accounts receivable will be sufficient to fund ADMA’s operations, as currently conducted, into the fourth quarter of 2021. In order to have sufficient cash to fund its operations thereafter, the Company anticipates it will need to raise additional capital before the end of the fourth quarter of 2021. These estimates may change based upon several factors, including the success of the Company’s commercial sales of its products, manufacturing ramp-up activities, the acceptability of ADMA’s immune globulin products by physicians, patients or payers and the various financing options that may be available to the Company. In addition, the Company’s end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months or potentially longer, requiring substantial investments in raw material plasma and other manufacturing materials. The Company currently has no firm commitments for additional financing, and there can be no assurance that the Company will be able to secure additional financing on terms that are acceptable to the Company, or at all. Furthermore, if the Company’s assumptions underlying its estimated expenses and revenues are incorrect, it may have to raise additional capital sooner than currently anticipated.

Due to numerous risks and uncertainties associated with FDA review, inspections and approvals related to the Company’s products or the labeled indications of such products, ongoing compliance requirements and capacity expansion efforts at the Company’s Boca Facility and future commercialization of the Company’s products, including the Company’s ability to obtain adequate quantities of FDA-approved plasma with proper specifications on acceptable terms for use in the Company’s manufacturing process, as well as the additional uncertainties surrounding the COVID-19 pandemic (see Note 10), the Company is unable to estimate with certainty the amounts of increased capital outlays and operating expenditures required to fund its commercial and development activities. The Company’s current estimates may be subject to change as circumstances regarding its business requirements evolve. Failure to secure any necessary financing in a timely manner and on commercially reasonable terms could have a material adverse effect on the Company’s business plan and financial performance and it could be forced to delay or discontinue its commercialization, product development or clinical activities or delay or discontinue the approval efforts for any of the Company’s products or product candidates. The Company has reported cumulative losses since inception in June 2004 through March 31, 2021 of $358.8 million. As such, these factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of asset carrying amounts and the classification of liabilities that might be necessary from the outcome of this uncertainty.

The Company may decide to raise capital through public or private equity offerings or debt financings, or obtain a bank credit facility or enter into corporate collaboration and licensing arrangements. The sale of additional equity or debt securities, if convertible, could result in dilution to the Company’s existing stockholders and, in such event, the market value of its common stock may decline. The incurrence of additional indebtedness would result in increased fixed obligations and could also result in covenants that would restrict the Company’s operations or other financing alternatives. In addition, the Company is exploring additional contract manufacturing arrangements and other business development opportunities, which may provide additional liquidity to the Company.

During the three months ended March 31, 2021, the Company raised $41.9 million from the open market sale agreement, as amended, (the “Sale Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company could offer and sell, from time to time, at its option, through or to Jefferies, shares of the Company’s common stock (see Note 8). As of March 31, 2021, the remaining gross balance that could be raised under the Sale Agreement was approximately $19.0 million.

There can be no assurance that the Company’s approved products will be commercially viable, or that research and development, plant capacity expansion, plasma center build-outs or other capital improvements will be successfully completed or that any product developed in the future will be approved. The Company is subject to risks common to companies in the biotechnology and pharmaceutical manufacturing industries including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2021

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (the “FASB”).

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 25, 2021. The accompanying consolidated balance sheet as of December 31, 2020 was derived from the audited financial statements as of and for the year ended December 31, 2020. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position as of March 31, 2021 and its results of operations, changes in equity and cash flows for the three months ended March 31, 2021.

During the three months ended March 31, 2021 and 2020, comprehensive loss was equal to the net loss amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year.

Use of estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards granted under the Company’s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company’s deferred tax assets.

Fair value of financial instruments

The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company’s senior secured term loan (see Note 7) approximates fair value due to the variable interest rate on this debt.

Accounts receivable

Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are recognized in the period the related revenue is recorded. The Company extends credit to its customers based upon an evaluation of each customer's financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis. Based on these evaluations, the Company has concluded that its credit risk is minimal. At March 31, 2021, five customers accounted for an aggregate of 90% of the Company’s total accounts receivable, and at December 31, 2020, three customers accounted for approximately 92% of the Company’s total accounts receivable.

Inventories

Raw materials inventory consists of various materials purchased from suppliers, including normal source plasma, used in the production of the Company’s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable supplies and depreciation. The allocation of Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company’s products relative to the total square footage of the facility.

Inventories, including plasma intended for resale and plasma intended for internal use in the Company’s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs associated with the production of conformance or engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.

Goodwill

Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at March 31, 2021 and December 31, 2020 was $3.5 million. All of the Company’s goodwill is attributable to its ADMA BioManufacturing business segment and is related to a 2017 acquisition transaction.

Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the reporting unit’s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year. The Company’s annual goodwill impairment test as of October 1, 2020 did not result in a goodwill impairment charge, and the Company did not record any impairment charges related to goodwill for the three months ended March 31, 2021 and 2020.

Impairment of long-lived assets

The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset’s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the three months ended March 31, 2021 and 2020, the Company determined that there was no impairment of its long-lived assets.

Revenue recognition

Revenues for the three months ended March 31, 2021 and 2020 are comprised of (i) revenues from the sale of the Company’s immunoglobulin products, BIVIGAM, ASCENIV and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company’s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.

Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company’s immunoglobulin products is recognized when the product reaches the customer’s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks and other wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.

Product revenues from the sale of human plasma collected at the Company’s plasma collection centers are recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.

For the three months ended March 31, 2021, five customers represented an aggregate of 86% of the Company’s consolidated revenues. For the three months ended March 31, 2020, three customers represented an aggregate of82% of the Company’s consolidated revenues.

Cost of product revenue

Cost of product revenue includes costs associated with the manufacture of the Company’s FDA approved products, intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.

Loss per common share

Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants, using the treasury stock method. Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be anti-dilutive. As a result, no potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts as the Company reported a net loss for all periods presented. For the three months ended March 31, 2021 and 2020, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:

	For the Three Months Ended March 31,
	2021		2020
Stock options		8,103,165		6,753,354
Restricted stock units		730,994		333,500
Warrants		4,528,160		2,138,160
		13,362,319		9,225,014

Stock-based compensation

The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company’s equity incentive plans generally have a four-year vesting period and a term of 10 years. Pursuant to ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), the Company has elected not to establish a forfeiture rate, as stock-based compensation expense related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.

Income Taxes

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2016 and for previous periods as it relates to the Company’s net operating loss carryforwards.

In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of March 31, 2021 and December 31, 2020, and during the three months ended March 31, 2021 and 2020, the Company recognized no adjustments for uncertain tax positions.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326) (“ASU 2016-13”), which requires financial assets to be presented at the net amount expected to be collected, with an allowance for credit losses to be deducted from the amortized cost basis of the financial asset such that the net carrying value of the asset is presented as the amount expected to be collected. Under ASU 2016-13, the entity’s statement of operations is required to reflect the measurement of credit losses for newly recognized financial assets, as well as expected increases or decreases in expected credit losses that have taken place during the period. For public business entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019. The Company adopted ASU No. 2016-13 on January 1, 2020, and the adoption of this update did not have a significant impact on the Company’s consolidated financial statements.

INVENTORIES

3 Months Ended

Mar. 31, 2021

INVENTORIES

3. INVENTORIES

3. INVENTORIES

The following table provides the components of inventories:

	March 31, 2021		December 31, 2020

Raw materials	$	38,411,316	$	32,044,393
Work-in-process		34,560,999		30,293,288
Finished goods		21,173,885		19,197,918
Total inventories	$	94,146,200	$	81,535,599

Raw materials includes plasma and other materials expected to be used in the production of BIVIGAM, ASCENIV and Nabi-HB, as there are alternative uses for these materials that provide a probable future benefit or will be consumed in the production of goods expected to be available for sale. All other activities and materials associated with the production of inventories used in research and development activities are expensed as incurred.

Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company’s immunoglobulin products. Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available for commercial sale, as well as plasma collected at the Company’s plasma collection centers which is expected to be sold to third-party customers.

INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2021

INTANGIBLE ASSETS

4. INTANGIBLE ASSETS

4. INTANGIBLE ASSETS

Intangible assets at March 31, 2021 and December 31, 2020 consist of the following:

	March 31, 2021						December 31, 2020
			Accumulated						Accumulated
	Cost		Amortization		Net		Cost		Amortization		Net
Trademark and other intangible rights related to Nabi-HB	$	4,100,046	$	2,245,263	$	1,854,783	$	4,100,046	$	2,098,833	$	2,001,213
Rights to intermediates		907,421		496,921		410,500		907,421		464,513		442,908
Customer contract		1,076,557		1,076,557		-		1,076,557		1,076,557		-
	$	6,084,024	$	3,818,741	$	2,265,283	$	6,084,024	$	3,639,903	$	2,444,121

All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets for the three months ended March 31, 2021 and 2020 was $0.2 million. Estimated aggregate future aggregate amortization expense is expected to be as follows:

Remainder of 2021	$	536,514
2022		715,352
2023		715,352
2024		298,065

PROPERTY AND EQUIPMENT

3 Months Ended

Mar. 31, 2021

PROPERTY AND EQUIPMENT

5. PROPERTY AND EQUIPMENT

5. PROPERTY AND EQUIPMENT

Property and equipment and related accumulated depreciation are summarized as follows:

	March 31, 2021			December 31, 2020
Manufacturing and laboratory equipment	$	14,774,354		$	14,468,874
Office equipment and computer software		3,456,610			3,253,528
Furniture and fixtures		2,057,257			2,039,398
Construction in process		5,932,680			3,336,557
Leasehold improvements		5,272,008			5,272,490
Land		4,339,441			4,339,441
Buildings and building improvements		18,247,277			17,746,744
		54,079,627			50,457,032
Less: Accumulated depreciation		(9,904,014	)		(8,863,942	)
Total property, plant and equipment, net	$	44,175,613		$	41,593,090

Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset’s estimated useful life. Land is not depreciated. The buildings were assigned a useful life of 30 years. Property and equipment other than land and buildings have useful lives ranging from three to 10 years. Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.

The Company recorded depreciation expense on property and equipment for the three months ended March 31, 2021 and 2020 of $1.1 million and $0.6 million, respectively.

ACCRUED EXPENSES AND OTHER LIABILITIES

3 Months Ended

Mar. 31, 2021

ACCRUED EXPENSES AND OTHER LIABILITIES

6. ACCRUED EXPENSES AND OTHER LIABILITIES

6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITES

Accrued expenses and other current liabilities at March 31, 2021 and December 31, 2020 are as follows:

	March 31, 2021		December 31, 2020
Accrued rebates	$	3,042,550	$	2,604,245
Accrued distribution fees		1,503,680		828,120
Accrued payroll		1,335,383		734,972
Accrued testing		1,168,270		779,660
Accrued incentives		773,721		3,210,884
Other		768,538		207,262
Total accrued expenses and other current liabilities	$	8,592,142	$	8,365,143

DEBT

3 Months Ended

Mar. 31, 2021

DEBT

7. DEBT

7. DEBT

A summary of outstanding senior notes payable is as follows:

	March 31, 2021			December 31, 2020
Notes payable	$	100,000,000		$	100,000,000
Less:
Debt discount		(6,587,340	)		(7,031,134	)
Senior notes payable	$	93,412,660		$	92,968,866

Under the Credit Agreement and Guaranty, as amended from time to time, (the “Perceptive Credit Agreement”) with Perceptive Credit Holdings II, LP, as the lender and administrative agent (“Perceptive”), the Company has a principal balance outstanding to Perceptive in the form of senior secured notes payable to Perceptive aggregating to $100.0 million with a maturity date of March 1, 2024 (the “Maturity Date”), subject to acceleration pursuant to the Perceptive Credit Agreement, including upon an Event of Default (as defined in the Perceptive Credit Agreement). On the Maturity Date, the Company will pay Perceptive the entire outstanding principal amount and any accrued and unpaid interest thereon. Prior to the Maturity Date, there are no scheduled principal payments due under the Perceptive Credit Agreement.

Borrowings under the Perceptive Credit Agreement bear interest at a rate per annum equal to 7.5% plus the greater of (i) one-month LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an Event of Default, the interest rate will automatically increase by an additional 400 basis points. Accrued interest is payable to Perceptive on the last day of each month during the term of the Perceptive Credit Facility. The rate of interest in effect as of March 31, 2021 was 11.0%, and the Company paid interest to Perceptive during the three months ended March 31, 2021 and 2020 in the amount of $2.8 million and $2.0 million, respectively.

All of the Company’s obligations under the Perceptive Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company’s tangible and intangible assets, including intellectual property and all of the equity interests in the Company’s subsidiaries. The Perceptive Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. The negative covenants restrict or limit the ability of the Company and its subsidiaries to, among other things and subject to certain exceptions contained in the Perceptive Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company’s or its subsidiaries’ business activities; make certain Investments or Restricted Payments (each as defined in the Perceptive Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company’s ability to make loan repayments under the Perceptive Credit Agreement. In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ended June 30, 2019, report revenues for the trailing 12-month period that exceed the amounts set forth in the Perceptive Credit Agreement, which range from $7.0 million for the fiscal quarter ended June 30, 2019 to $55.0 million for the fiscal quarter ending December 31, 2021. At March 31, 2021, the Company was in compliance with all of the covenants contained in the Perceptive Credit Agreement.

As a result of the fees paid to Perceptive and the value of the warrants issued to Perceptive under the terms of the Perceptive Credit Agreement, the Company recognized an aggregate discount on the senior secured notes in the amount of $7.1 million. The Company records debt discount as a reduction to the face amount of the debt, and the debt discount is amortized as interest expense over the life of the debt using the interest method. Based on the fair value of the Perceptive Warrants and the aggregate amount of fees and expenses associated with obtaining the Perceptive Credit Facility, the effective interest rate on senior secured notes payable to Perceptive as of March 31, 2021 was approximately 13.7%.

STOCKHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2021

STOCKHOLDERS' EQUITY

8. STOCKHOLDERS' EQUITY

8. STOCKHOLDERS’ EQUITY

Preferred Stock

The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par value per share. There were no shares of preferred stock outstanding at March 31, 2021 and December 31, 2020.

Common Stock

As of March 31, 2021 and December 31, 2020, the Company was authorized to issue 150,000,000 shares of its common stock, $0.0001 par value per share, and 123,044,981 and 104,902,888 shares of common stock were outstanding as of March 31, 2021 and December 31, 2020, respectively. After giving effect to the 17,080,606 shares reserved for outstanding warrants and awards issued or reserved for future issuance under the Company’s equity incentive plans, as of March 31, 2021 there were 9,874,413 shares of common stock available for issuance.

On August 5, 2020, the Company entered into the Sale Agreement with Jefferies (see Note 1), pursuant to which the Company could offer and sell, from time to time, at its option, through or to Jefferies, up to an aggregate of $50 million of shares of the Company’s common stock. On November 5, 2020 and February 3, 2021, the Company and Jefferies amended the Sale Agreement to provide for an increase in the aggregate offering amount under the Sale Agreement such that, as of February 3, 2021, the Company could sell shares having an aggregate offering price of up to $105.4 million. During the three months ended March 31, 2021, the Company issued and sold 18,080,708 shares of common under the Sale Agreement and received net proceeds of $41.9 million.

On February 11, 2020, the Company completed an underwritten public offering of 23,500,000 shares of its common stock for gross proceeds of $82.3 million. On February 21, 2020, the Company sold an additional 3,525,000 shares pursuant to the underwriters’ exercise of their option to purchase additional shares of the Company’s common stock for additional gross proceeds of $12.3 million. The Company received net proceeds, after underwriting discounts and other expenses associated with the offering, of approximately $88.7 million.

Warrants

At March 31, 2021 and December 31, 2020, the Company had outstanding warrants to purchase an aggregate of 4,528,160 shares of common stock, with a weighted average exercise price of $2.82 per share and expiration dates ranging between June 2022 and December 2030.

Equity Incentive Plans

The fair value of stock options granted under the Company’s 2007 Employee Stock Option Plan (the “2007 Plan”) and the ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan, as amended and restated (the “2014 Plan”), was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. The following assumptions were used to determine the fair value of options granted during the three months ended March 31, 2021 and 2020:

	Three Months Ended March 31,
	2021		2020
Expected term		5.5 - 6.3 years		5.8 - 6.3 years
Volatility		69%		62%
Dividend yield		0.0		0.0
Risk-free interest rate		0.80-% 1.04%		0.47-1.68%

During the three months ended March 31, 2021 and 2020, the Company granted options to purchase an aggregate of 1,441,050 and 1,158,900 shares of common stock, respectively, to its directors, employees and certain third-party service providers. The weighted average remaining contractual life of stock options outstanding and expected to vest at March 31, 2021 is 7.0 years. The weighted average remaining contractual life of stock options exercisable at March 31, 2021 is 4.8 years.

A summary of the Company’s option activity under the 2007 Plan and 2014 Plan and related information is as follows:

	Shares			Weighted Average Exercise Price
Options outstanding, vested and expected to vest at December 31, 2020		6,922,931		$	4.40
Forfeited		(57,420	)	$	3.40
Expired		(203,396	)	$	5.12
Granted		1,441,050		$	2.35
Exercised		-		$	-
Options outstanding, vested and expected to vest at March 31, 2021		8,103,165		$	4.02

Options exercisable		4,855,296		$	4.81

As of March 31, 2021, the Company had $5.3 million of unrecognized compensation expense related to options granted under the Company’s equity incentive plans, which is expected to be recognized over a weighted-average period of 2.7 years.

During the three months ended March 31, 2021 and 2020, the Company granted Restricted Stock Units (“RSUs”) representing an aggregate of 492,744 and 341,000 shares, respectively, to certain management employees of the Company and to members of its Board of Directors. The RSUs vest annually over a period of four years for employees and semi-annually over a period of one year for directors. Total compensation expense related to unvested RSUs for the three months ended March 31, 2021 and 2020 was $0.1 million and $28,000, respectively. During the three months ended March 31, 2021, 87,750 shares vested in connection with grants of RSUs. With respect to these vested RSUs, 26,365 shares valued at approximately $59,000 were withheld by the Company to cover employees’ tax liabilities. On March 25, 2021, these shares were retired by the Company and were no longer outstanding as of March 31, 2021. A summary of the Company’s unvested RSU activity and related information is as follows:

	Shares			Weighted Average Grant Date Fair Value
Balance at December 31, 2020		326,000		$	2.81
Granted		492,744		$	2.35
Vested		(87,750	)	$	2.81
Forfeited		-		$	-
Balance at March 31, 2021		730,994		$	2.50

As of March 31, 2021, the Company had $1.8 million of unrecognized compensation expense related to unvested RSUs granted under the Company’s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.5 years.

Total stock-based compensation expense for all awards granted under the Company’s equity incentive plans for the three months ended March 31, 2021 and 2020 is as follows:


	2021		2020
Research and development	$	105,227	$	93,574
Plasma center operating expenses		10,818		7,244
Selling, general and administrative		588,491		523,889
Cost of product revenue		76,861		51,841
Total stock-based compensation expense	$	781,397	$	676,548

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2021

RELATED PARTY TRANSACTIONS

9. RELATED PARTY TRANSACTIONS

9. RELATED PARTY TRANSACTIONS

The Company leases an office building and equipment from Areth, LLC (“Areth”) pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time. Rent expense for the three months ended March 31, 2021 and 2020 amounted to $30,000. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company’s Board of Directors, and Adam S. Grossman, the Company’s President and Chief Executive Officer. The Company also reimburses Areth for office and building related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the three months ended March 31, 2021 and 2020. In addition, during the three months ended March 31, 2021, the Company purchased certain specialized medical equipment and services related to the Company’s plasma collection centers, as well as personal protective equipment, from GenesisBPS and its affiliates (“Genesis”), which were not material to the consolidated financial statements. Genesis is owned by Dr. Grossman and Adam Grossman.

See Note 7 for a discussion of the Company’s credit facility and related transactions with Perceptive, a holder of more than 10% of the Company’s common stock.

In connection with the February 2020 public offering of the Company’s common stock (see Note 8) on February 11, 2020: (i) Perceptive Advisors, a principal stockholder of ADMA, purchased 4,563,700 shares of common stock through one of its affiliates, (ii) Dr. Grossman purchased 22,857 shares of common stock directly and 22,857 shares indirectly through an entity he controls, (iii) Lawrence P. Guiheen, a director of the Company, purchased 20,000 shares of common stock, (iv) Mr. Grossman purchased 28,571 shares of common stock directly and 57,143 shares indirectly through an entity he controls, (v) Brian Lenz, the Company’s Executive Vice President and Chief Financial Officer, purchased 7,142 shares of common stock, and (vi) Dr. James Mond, the Company’s Chief Scientific Officer and Chief Medical Officer, purchased 4,285 shares of common stock, all at the public offering price of $3.50 per share.

COMMITMENT AND CONTINGENCIES

3 Months Ended

Mar. 31, 2021

COMMITMENT AND CONTINGENCIES

10. COMMITMENTS AND CONTINGENCIES

10. COMMITMENTS AND CONTINGENCIES

General Legal Matters

From time to time the Company is or may become subject to certain legal proceedings and claims arising in connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company’s liquidity, results of operations or financial condition.

COVID-19 Pandemic

The Company continues to monitor the ongoing developments related to the COVID-19 pandemic and its impacts to the Company’s commercial and manufacturing operations and plasma collection facilities, including collections of source plasma, procurement of raw materials and packaging materials, a portion of which are sourced internationally, and the testing of finished drug product that is required prior to its availability for commercial sale. A substantial portion of such testing has historically been performed by contract laboratories outside the United States.

The Company has experienced some delays with final drug product release testing by third-party vendors. In response to these delays, the Company added additional release testing laboratories to its FDA-approved consortium listed in its drug approval documents which the Company believes has adequately addressed this issue. In addition, due to a combination of previous state and local “shelter-in-place” orders, as well as government stimulus packages, persisting social distancing measures and varying roll-outs of vaccinations by state, the Company has experienced lower than normal donor collections at its FDA approved plasma collection centers. The Company was also subject to delays in shipments of source plasma from its contracted third-party suppliers, as well as delays in deliveries for personal protective equipment, reagents and other non-plasma raw materials and supplies used in the manufacture and distribution of its products. The Company is also subject to supply chain delays as a result of certain of its suppliers diverting significant resources towards the rapid development and distribution of COVID 19 vaccines. The COVID-19 pandemic has also impacted, to a certain degree, the Company’s customer engagement initiatives, whereby ADMA’s sales and medical affairs field personnel have faced difficulties communicating directly with physicians and other healthcare professionals, as well as the cancellation or postponement of a number of key scientific and medical meetings, further limiting the Company’s ability to communicate with potential customers. The Company has implemented a comprehensive suite of virtual engagement initiatives, however, clinician engagement has been reduced due to rapidly evolving COVID-19 priorities at U.S. medical centers.

The pandemic could also impact the Company’s ability to interact with the FDA or other regulatory authorities and may result in delays in the conduct of inspections or review of pending applications or submissions. During the second quarter of 2021, the Company was notified by the FDA that its submission for the approval of its in-house fill-finish process utilizing a recently installed aseptic filling machine will require a site inspection, either in person or virtually, of the Boca Facility. Taking into account ongoing travel restrictions resulting from the pandemic, the Company believes that the inspection could be completed before the end of the fourth quarter of 2021, however no assurances can be provided as to the timing of such an inspection or the timing as to when the FDA may adjust its restrictions due to COVID-19.

Notwithstanding the foregoing, the COVID-19 pandemic to date has not had a material impact on the Company’s financial condition or results of operations, and the Company does not believe that its production operations at the Boca Facility, the Company’s contract fill/finishers or its plasma collection facilities have been significantly impacted by the COVID-19 pandemic. As a result, the Company does not anticipate and has not experienced any material impairments with respect to any of its long-lived assets, including the Company’s property and equipment, goodwill or intangible assets.

Although the COVID-19 pandemic has not, to date, materially adversely impacted the Company’s capital and financial resources, because the Company is unable to determine the ultimate severity or duration of the pandemic or its long-term effects on, among other things, the global, national or local economies, the capital and credit markets or the Company’s workforce, customers or our suppliers, at this time the Company is unable to predict whether COVID-19 will have a material adverse impact on the Company’s business, financial condition, liquidity and results of operations.

Vendor Commitments

Pursuant to the terms of a plasma purchase agreement with BPC dated as of November 17, 2011 (the “2011 Plasma Purchase Agreement”), the Company agreed to purchase from BPC an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum volume from BPC, but may also collect high-titer RSV plasma from up to five wholly-owned ADMA plasma collection facilities. During 2015, the Company and BPC amended the 2011 Plasma Purchase Agreement to allow the Company the ability to collect its raw material RSV high-titer plasma from other third-party collection organizations, thus allowing the Company to expand its reach for raw material supply as it executes its commercialization plans for ASCENIV. Unless terminated earlier, the 2011 Plasma Purchase Agreement expires in June 2027, after which it may be renewed for two additional five-year periods if agreed to by the parties. As part of the closing of the Biotest Transaction, the parties amended the 2011 Plasma Purchase Agreement to extend the initial term through the ten-year anniversary of the closing date of the Biotest Transaction. On December 10, 2018, BPC assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (“Grifols”) as its successor-in-interest, effective January 1, 2019. On January 1, 2019, Grifols and the Company entered into an additional amendment to the 2011 Plasma Purchase Agreement for the purchase of source plasma containing antibodies to RSV from Grifols. Pursuant to this amendment, until January 1, 2022, the Company may purchase RSV plasma from Grifols from the two plasma collection centers that were transferred to BPC on January 1, 2019 at a price equal to cost plus five percent (5%) (without any additional increase due to inflation).

On June 6, 2017, the Company and BPC entered into a Plasma Supply Agreement pursuant to which BPC supplies, on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a 10-year term. On July 19, 2018, the Company and BPC entered into an amendment to the Plasma Supply Agreement to provide, among other things, that in the event BPC elects not to supply in excess of ADMA BioManufacturing’s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit percentage of the price that ADMA BioManufacturing pays to BPC, then BPC shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, BPC assigned its rights and obligations under the Plasma Supply Agreement to Grifols, effective January 1, 2019.

On June 6, 2017, the Company and BPC entered into a Plasma Purchase Agreement (the “2017 Plasma Purchase Agreement”), pursuant to which ADMA BioManufacturing purchases normal source plasma (“NSP”) from BPC at agreed upon annual quantities and prices. The 2017 Plasma Purchase Agreement has an initial term of five years after which the 2017 Plasma Purchase Agreement may be renewed for additional two terms of two years each upon the mutual written consent of the parties. On July 19, 2018, the Company and BPC entered into an amendment to the 2017 Plasma Purchase Agreement to, among other things, provide agreed upon amounts of normal source plasma to be supplied by BPC to ADMA BioManufacturing in calendar year 2019 at a specified price per liter, provided that ADMA BioManufacturing delivers a valid purchase order to BPC. Additionally, pursuant to the amendment to the 2017 Plasma Purchase Agreement, BPC agreed that, for calendar years 2020 and 2021, it shall supply no less than a high double-digit percentage of ADMA BioManufacturing’s requested NSP amounts, provided that such requested NSP amounts are within an agreed range, at a price per liter to be mutually determined. Furthermore, pursuant to the amendment to the 2017 Plasma Purchase Agreement, in the event BPC fails to supply ADMA BioManufacturing with at least a high double-digit percentage of ADMA BioManufacturing’s requested NSP amounts, BPC shall promptly reimburse ADMA BioManufacturing the difference in price ADMA BioManufacturing incurs due to BPC’s election not to supply NSP to ADMA BioManufacturing in such amounts as requested. On December 10, 2018, BPC assigned its rights and obligations under the Plasma Purchase Agreement to Grifols, effective January 1, 2019.

Effective as of May 12, 2021, the Company and Grifols amended the foregoing 2017 Plasma Purchase Agreement whereby, among other things, term of the agreement was extended through December 31, 2022, while certain historical provisions were deleted. In order to maintain a reliable supply of raw material plasma thereafter, the Company is in late-stage discussion with multiple third-party suppliers of NSP to supplement the 2017 Plasma Purchase Agreement, while the Company has also increased the number of planned plasma collection center buildouts and is continuing to increase its plasma collection capabilities at its ADMA BioCenters plasma collection centers business segment.

The Company purchases substantially all of its raw material plasma from Grifols. For the three months ended March 31, 2021, plasma purchases from Grifols totaled $12.7 million, or approximately 72% of the Company’s total inventory purchases. For the three months ended March 31, 2020, plasma purchases from Grifols totaled approximately $2.0 million, representing approximately 46% of the Company’s total inventory purchases.

Post-marketing commitments

In connection with the approval of the BLA for BIVIGAM, on December 19, 2012 Biotest committed to perform two additional post-marketing studies, a pediatric study to evaluate the efficacy and safety of BIVIGAM in children and adolescents, and a post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal impairment in BIVIGAM-treated patients with primary humoral immunodeficiency. These studies are still pending completion. ADMA has assumed the remaining obligations, and the costs of the studies will be expensed as incurred as research and development expenses. The Company currently expects both studies to be completed by June of 2023.

In connection with the FDA’s approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. This study is required to be completed by June of 2023.

Employment contracts

The Company has entered into employment agreements with its executive management team consisting of its President and Chief Executive Officer, its Executive Vice President, Chief Medical Officer and Chief Scientific Officer and its Executive Vice President and Chief Financial Officer.

Other commitments

In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company’s request in such capacities. The Company’s maximum exposure under these arrangements is unknown as of March 31, 2021. The Company does not anticipate recognizing any significant losses relating to these arrangements.

SEGMENTS

3 Months Ended

Mar. 31, 2021

SEGMENTS

11. SEGMENTS

11. SEGMENTS

The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company’s ADMA BioManufacturing segment reflects the Company’s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1). The Plasma Collection Centers segment as of March 31, 2021 consists of two FDA-licensed source plasma collection facilities, an additional plasma collection facility for which an FDA license is pending, and four other plasma collection facilities under various stages of development. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables:

Three Months Ended March 31, 2021
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated

Revenues	$	13,421,043		$	2,591,867		$	35,708		$	16,048,618

Cost of product revenue		15,449,757			2,320,365			-			17,770,122

Loss from operations		(9,505,689	)		(1,970,841	)		(3,687,719	)		(15,164,249	)

Interest and other expense, net		(21,513	)		(384	)		(3,193,795	)		(3,215,692	)

Net loss		(9,527,202	)		(1,971,225	)		(6,881,514	)		(18,379,941	)

Capital expenditures		1,012,980			1,558,181			-			2,571,161
Depreciation and amortization expense		1,009,770			217,991			1,867			1,229,628
Total assets		156,535,177			17,397,612			61,734,239			235,667,028

Three Months Ended March 31, 2020
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated

Revenues	$	7,743,275		$	2,420,761		$	35,708		$	10,199,744

Cost of product revenue		14,451,954			2,377,272			-			16,829,226

Loss from operations		(12,476,144	)		(457,155	)		(3,836,487	)		(16,769,786	)

Interest and other expense, net		(238,873	)		-			(2,236,571	)		(2,475,444	)

Net loss		(12,715,017	)		(457,155	)		(6,073,058	)		(19,245,230	)

Capital expenditures		1,914,614			160,262			-			2,074,876
Depreciation and amortization expense		674,973			111,289			2,576			788,838
Total assets		104,645,897			5,376,807			100,501,123			210,523,827

LEASE OBLIGATIONS

3 Months Ended

Mar. 31, 2021

LEASE OBLIGATIONS

12. LEASE OBLIGATIONS

12. LEASE OBLIGATIONS

The Company leases certain properties and equipment for its ADMA BioCenters subsidiary and certain equipment for its ADMA BioManufacturing subsidiary, which leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2032. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to make lease payments arising from the lease. Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company’s incremental borrowing rate of 13%. The Company’s lease expense is recognized on a straight-line basis over the lease term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses. Aggregate lease expense for the Company’s leases for the three months ended March 31, 2021 and 2020 was approximately $0.3 million and $0.1 million, respectively. Cash paid for the Company’s leases for the three months ended March 31, 2021 and 2020 was approximately $0.2 million and $0.1 million, respectively.

During the three months ended March 31, 2021, the Company recognized additional right to use assets and corresponding lease liabilities of $2.1 million in connection with two new property leases where the Company intends to open two additional plasma collection facilities. Including a finance lease the Company entered into in June 2018, the Company has aggregate lease liabilities of $6.7 million and $4.7 million as of March 31, 2021 and December 31, 2020, respectively, which are comprised primarily of the leases for the Company’s plasma collection centers and an administrative office lease related to the Company’s ADMA BioCenters subsidiary. The Company’s operating leases have a weighted average remaining term of 9.3 years. Scheduled payments under the Company’s lease obligations are as follows:

Remainder of 2021	$	852,315
Year ended December 31, 2022		1,374,513
2023		1,386,375
2024		1,257,300
2025		1,261,052
2026		990,732
Thereafter		4,718,836
Total payments		11,841,123
Less: imputed interest		(5,103,624	)
Current portion		(317,910	)
Balance at March 31, 2021	$	6,419,589

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

3 Months Ended

Mar. 31, 2021

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

13. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

13. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Supplemental cash flow information for the three months ended March 31, 2021 and 2020 is as follows:

	2021		2020
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	2,751,956	$	2,017,866
Noncash Financing and Investing Activities:
Equipment acquired reflected in accounts payable and accrued liabilities	$	1,797,249	$	2,340,337
Right-to-use assets in exchange for lease obligations	$	2,073,627	$	545,630

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2021

SUBSEQUENT EVENTS

14. SUBSEQUENT EVENTS

14. SUBSEQUENT EVENTS

Between April 1, 2021 and May 7, 2021, the Company sold an additional 5,144,647 shares of its common stock under the Sale Agreement and received net proceeds in the amount of $10.9 million, which leaves a remaining gross balance that can be raised under the Sale Agreement of approximately $7.9 million.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2021

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

Use of estimates

Fair value of financial instruments

Accounts receivable

Inventories

Goodwill

Impairment of long-lived assets

Revenue recognition

Cost of product revenue

Loss per common share

	For the Three Months Ended March 31,
	2021		2020
Stock options		8,103,165		6,753,354
Restricted stock units		730,994		333,500
Warrants		4,528,160		2,138,160
		13,362,319		9,225,014

Stock-based compensation

Income Taxes

Recent Accounting Pronouncements

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2021

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of dilutive securities

	For the Three Months Ended March 31,
	2021		2020
Stock options		8,103,165		6,753,354
Restricted stock units		730,994		333,500
Warrants		4,528,160		2,138,160
		13,362,319		9,225,014

INVENTORIES (Tables)

3 Months Ended

Mar. 31, 2021

INVENTORIES

Schedule of inventory

	March 31, 2021		December 31, 2020

Raw materials	$	38,411,316	$	32,044,393
Work-in-process		34,560,999		30,293,288
Finished goods		21,173,885		19,197,918
Total inventories	$	94,146,200	$	81,535,599

INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2021

INTANGIBLE ASSETS

Schedule of Intangible assets

	March 31, 2021						December 31, 2020
			Accumulated						Accumulated
	Cost		Amortization		Net		Cost		Amortization		Net
Trademark and other intangible rights related to Nabi-HB	$	4,100,046	$	2,245,263	$	1,854,783	$	4,100,046	$	2,098,833	$	2,001,213
Rights to intermediates		907,421		496,921		410,500		907,421		464,513		442,908
Customer contract		1,076,557		1,076,557		-		1,076,557		1,076,557		-
	$	6,084,024	$	3,818,741	$	2,265,283	$	6,084,024	$	3,639,903	$	2,444,121

Intangible asset future aggregate amortization expense

Remainder of 2021	$	536,514
2022		715,352
2023		715,352
2024		298,065

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2021

PROPERTY AND EQUIPMENT

Schedule of property and equipment

	March 31, 2021			December 31, 2020
Manufacturing and laboratory equipment	$	14,774,354		$	14,468,874
Office equipment and computer software		3,456,610			3,253,528
Furniture and fixtures		2,057,257			2,039,398
Construction in process		5,932,680			3,336,557
Leasehold improvements		5,272,008			5,272,490
Land		4,339,441			4,339,441
Buildings and building improvements		18,247,277			17,746,744
		54,079,627			50,457,032
Less: Accumulated depreciation		(9,904,014	)		(8,863,942	)
Total property, plant and equipment, net	$	44,175,613		$	41,593,090

ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2021

ACCRUED EXPENSES AND OTHER LIABILITIES

Schedule of Accrued expenses and other current liabilities

	March 31, 2021		December 31, 2020
Accrued rebates	$	3,042,550	$	2,604,245
Accrued distribution fees		1,503,680		828,120
Accrued payroll		1,335,383		734,972
Accrued testing		1,168,270		779,660
Accrued incentives		773,721		3,210,884
Other		768,538		207,262
Total accrued expenses and other current liabilities	$	8,592,142	$	8,365,143

DEBT (Tables)

3 Months Ended

Mar. 31, 2021

DEBT

Summary of notes payable

	March 31, 2021			December 31, 2020
Notes payable	$	100,000,000		$	100,000,000
Less:
Debt discount		(6,587,340	)		(7,031,134	)
Senior notes payable	$	93,412,660		$	92,968,866

STOCKHOLDERS EQUITY (Tables)

3 Months Ended

Mar. 31, 2021

STOCKHOLDERS' EQUITY

Schedule of assumptions

	Three Months Ended March 31,
	2021		2020
Expected term		5.5 - 6.3 years		5.8 - 6.3 years
Volatility		69%		62%
Dividend yield		0.0		0.0
Risk-free interest rate		0.80-% 1.04%		0.47-1.68%

Schedule of option activity

	Shares			Weighted Average Exercise Price
Options outstanding, vested and expected to vest at December 31, 2020		6,922,931		$	4.40
Forfeited		(57,420	)	$	3.40
Expired		(203,396	)	$	5.12
Granted		1,441,050		$	2.35
Exercised		-		$	-
Options outstanding, vested and expected to vest at March 31, 2021		8,103,165		$	4.02

Options exercisable		4,855,296		$	4.81

Schedule of compensation expense

	Shares			Weighted Average Grant Date Fair Value
Balance at December 31, 2020		326,000		$	2.81
Granted		492,744		$	2.35
Vested		(87,750	)	$	2.81
Forfeited		-		$	-
Balance at March 31, 2021		730,994		$	2.50

Schedule of stock-based compensation expense


	2021		2020
Research and development	$	105,227	$	93,574
Plasma center operating expenses		10,818		7,244
Selling, general and administrative		588,491		523,889
Cost of product revenue		76,861		51,841
Total stock-based compensation expense	$	781,397	$	676,548

SEGMENTS (Tables)

3 Months Ended

Mar. 31, 2021

SEGMENTS

Summarized segment financial information

Three Months Ended March 31, 2021
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated

Revenues	$	13,421,043		$	2,591,867		$	35,708		$	16,048,618

Cost of product revenue		15,449,757			2,320,365			-			17,770,122

Loss from operations		(9,505,689	)		(1,970,841	)		(3,687,719	)		(15,164,249	)

Interest and other expense, net		(21,513	)		(384	)		(3,193,795	)		(3,215,692	)

Net loss		(9,527,202	)		(1,971,225	)		(6,881,514	)		(18,379,941	)

Capital expenditures		1,012,980			1,558,181			-			2,571,161
Depreciation and amortization expense		1,009,770			217,991			1,867			1,229,628
Total assets		156,535,177			17,397,612			61,734,239			235,667,028

Three Months Ended March 31, 2020
	ADMA BioManufacturing			Plasma Collection Centers			Corporate			Consolidated

Revenues	$	7,743,275		$	2,420,761		$	35,708		$	10,199,744

Cost of product revenue		14,451,954			2,377,272			-			16,829,226

Loss from operations		(12,476,144	)		(457,155	)		(3,836,487	)		(16,769,786	)

Interest and other expense, net		(238,873	)		-			(2,236,571	)		(2,475,444	)

Net loss		(12,715,017	)		(457,155	)		(6,073,058	)		(19,245,230	)

Capital expenditures		1,914,614			160,262			-			2,074,876
Depreciation and amortization expense		674,973			111,289			2,576			788,838
Total assets		104,645,897			5,376,807			100,501,123			210,523,827

LEASE OBLIGATIONS (Tables)

3 Months Ended

Mar. 31, 2021

LEASE OBLIGATIONS

Schedule of future minimum lease payments

Remainder of 2021	$	852,315
Year ended December 31, 2022		1,374,513
2023		1,386,375
2024		1,257,300
2025		1,261,052
2026		990,732
Thereafter		4,718,836
Total payments		11,841,123
Less: imputed interest		(5,103,624	)
Current portion		(317,910	)
Balance at March 31, 2021	$	6,419,589

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)

3 Months Ended

Mar. 31, 2021

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Schedule of supplemental cash flow information

	2021		2020
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	2,751,956	$	2,017,866
Noncash Financing and Investing Activities:
Equipment acquired reflected in accounts payable and accrued liabilities	$	1,797,249	$	2,340,337
Right-to-use assets in exchange for lease obligations	$	2,073,627	$	545,630

ORGANIZATION AND BUSINESS (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Mar. 31, 2021	Feb. 03, 2021
Cash and cash equivalents		$ 62.0
Cumulative loss		358.8
Working capital		$ 156.1
Jefferies LLC [Member] \| Sale Agreement [Member]
Sales of common stock			$ 19.0
Proceeds from sales of common stock	$ 41.9

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Potentially dilutive securities	13,362,319	9,225,014
Warrants [Member]
Potentially dilutive securities	4,528,160	2,138,160	4,528,160
Restricted stock units [Member]
Potentially dilutive securities	730,994	333,500
Stock Options [Member]
Potentially dilutive securities	8,103,165	6,753,354

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Goodwill	$ 3,500,000		$ 3,500,000.0
Five Customers [Member]
Account receivables	90.00%
Revenues rate	86.00%
Three Customers [Member]
Account receivables		92.00%
Revenues rate		82.00%
Biotest License Agreement [Member]
Amortization period	22 years	22 years

INVENTORIES (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
INVENTORIES
Raw materials	$ 38,411,316	$ 32,044,393
Work-in-process	34,560,999	30,293,288
Finished goods	21,173,885	19,197,918
Total inventories	$ 94,146,200	$ 81,535,599

INTANGIBLE ASSETS (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Cost	$ 6,084,024	$ 6,084,024
Accumulated amortization	3,818,741	3,639,903
Net	2,265,283	2,444,121
Trademark and other intangible rights related to Nabi-HB
Cost	4,100,046	4,100,046
Accumulated amortization	2,245,263	2,098,833
Net	1,854,783	2,001,213
Right to intermediates
Cost	907,421	907,421
Accumulated amortization	496,921	464,513
Net	410,500	442,908
Customer contract
Cost	1,076,557	1,076,557
Accumulated amortization	1,076,557	1,076,557
Net	$ 0	$ 0

INTANGIBLE ASSETS (Details 1)	Mar. 31, 2021 USD ($)
INTANGIBLE ASSETS (Details)
Remaining of 2021	$ 536,514
2022	715,352
2023	715,352
2024	$ 298,065

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended
INTANGIBLE ASSETS (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
INTANGIBLE ASSETS
Amortization of intangible assets	$ 200,000	$ 200,000.0

PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Property, plant and equipments, gross	$ 54,079,627	$ 50,457,032
Less: accumulated depreciation	(9,904,014)	(8,863,942)
Total Property, plant and equipments, net	44,175,613	41,593,090
Manufacturing and laboratory equipment [Member]
Property, plant and equipments, gross	14,774,354	14,468,874
Office equipment and computer software [Member]
Property, plant and equipments, gross	3,456,610	3,253,528
Furniture and fixtures [Member]
Property, plant and equipments, gross	2,057,257	2,039,398
Construction in process [Member]
Property, plant and equipments, gross	5,932,680	3,336,557
Leasehold improvements [Member]
Property, plant and equipments, gross	5,272,008	5,272,490
Land [Member]
Property, plant and equipments, gross	4,339,441	4,339,441
Buildings and building improvements [Member]
Property, plant and equipments, gross	$ 18,247,277	$ 17,746,744

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Depreciation expense	$ 1.1	$ 0.6
Estimated useful life	30 years
Minimum [Member]
Estimated useful life	3 years
Maximum [Member]
Estimated useful life	10 years

ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
DEBT
Accrued rebates	$ 3,042,550	$ 2,604,245
Accrued distribution fees	1,503,680	828,120
Accrued payroll	1,335,383	734,972
Accrued testing	1,168,270	779,660
Accrued incentives	773,721	3,210,884
Other	768,538	207,262
Total accrued expenses and other current liabilities	$ 8,592,142	$ 8,365,143

DEBT (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
DEBT
Notes payable	$ 100,000,000	$ 100,000,000
Less: debt discount	(6,587,340)	(7,031,134)
Senior notes payable	$ 93,412,660	$ 92,968,866

DEBT (Details Narrative) - USD ($)	3 Months Ended
DEBT (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Effective interest rate	13.70%
Interest paid	$ 2,751,956	$ 2,017,866
Perceptive Credit Agreement [Member]
Security notes payable	7,100,000
Interest paid	$ 2,800,000	$ 2,000,000.0
Interest rate description	Perceptive Credit Agreement bear interest at a rate per annum equal to 7.5% plus the greater of (i) one-month LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an Event of Default, the interest rate will automatically increase by an additional 400 basis points. Accrued interest is payable to Perceptive on the last day of each month during the term of the Perceptive Credit Facility. The rate of interest in effect as of March 31, 2021 was 11.0%
Additional description	In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ended June 30, 2019, report revenues for the trailing 12-month period that exceed the amounts set forth in the Perceptive Credit Agreement, which range from $7.0 million for the fiscal quarter ended June 30, 2019 to $55.0 million for the fiscal quarter ending December 31, 2021. At March 31, 2021

STOCKHOLDERS EQUITY (Details)	3 Months Ended
STOCKHOLDERS EQUITY (Details)	Mar. 31, 2021	Mar. 31, 2020
Dividend yield	0.00%	0.00%
Volatility	69.00%	62.00%
Minimum [Member]
Expected term	5 years 6 months	5 years 9 months 18 days
Risk-free interest rate	0.80%	0.47%
Maximum [Member]
Expected term	6 years 3 months 18 days	6 years 3 months 18 days
Risk-free interest rate	1.04%	1.68%

STOCKHOLDERS EQUITY (Details 1) - $ / shares	3 Months Ended
STOCKHOLDERS EQUITY (Details 1) - $ / shares	Mar. 31, 2021	Mar. 31, 2020
Shares, Granted	1,441,050	1,158,900
Weighted Average Exercise Price [Member]
Weighted average exercise price, Beginning of period	$ 4.40
Weighted average exercise price, Forfeited	3.40
Weighted average exercise price, Expired	5.12
Weighted average exercise price, Granted	2.35
Weighted average exercise price, Exercised	0
Weighted average exercise price, Outstanding at end of period and expected to vest	4.02
Weighted average exercise price, Options exercisable	$ 4.81
Shares [Member]
Shares, Outstanding at beginning of period	6,922,931
Shares, Forfeited	(57,420)
Shares, Expired	(203,396)
Shares, Granted	1,441,050
Shares, Exercised	0
Shares, Outstanding at end of period and expected to vest	8,103,165
Shares, Options exercisable	4,855,296

STOCKHOLDERS EQUITY (Details 2)	3 Months Ended
STOCKHOLDERS EQUITY (Details 2)	Mar. 31, 2021 USD ($) $ / shares shares
Restricted stock units [Member]
Outstanding at beginning of period \| $	$ 326,000
Granted \| shares	492,744
Vested \| shares	(87,750)
Forfeited \| shares	0
Outstanding at end of period \| $	$ 730,994
Weighted Average Grant Date Fair Value [Member]
Weighted average grant date fair value, beginning	$ 2.81
Weighted average grant date fair value, Granted	2.35
Weighted average grant date fair value, Vested	2.81
Weighted average grant date fair value, Forfeited	0
Weighted Average Exercise Price at Ending Balance	$ 2.50

STOCKHOLDERS EQUITY (Details 3) - USD ($)	3 Months Ended
STOCKHOLDERS EQUITY (Details 3) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Total stock-based compensation expense	$ 781,397	$ 676,548
Cost of goods sold [Member]
Total stock-based compensation expense	76,861	51,841
Research and Development [Member]
Total stock-based compensation expense	105,227	93,574
Plasma Center Operating Expenses [Member]
Total stock-based compensation expense	10,818	7,244
Selling, General and Administrative [Member]
Total stock-based compensation expense	$ 588,491	$ 523,889

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		12 Months Ended
STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	Feb. 11, 2020	Feb. 21, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Aug. 05, 2020
Preferred stock, par value			$ 0.0001		$ 0.001
Preferred stock, outstanding			0		0
Preferred stock, shares authorized			10,000,000		10,000,000
Common stock, par value			$ 0.0001		$ 0.0001
Common stock, shares issued			123,044,981		104,902,888
Common stock, shares authorized			150,000,000		150,000,000
Common stock, shares outstanding			123,044,981		104,902,888
Underwritten public offering	23,500,000	3,525,000
Proceeds from issuance of shares	$ 82,300,000	$ 12,300,000	$ 41,912,515	$ 88,704,039
Net proceeds from the issuance of common stock		$ 88,700,000
Common stock issuable			9,874,413
Shares, Granted			1,441,050	1,158,900
Warrants outstanding			17,080,606
Weighted average exercise price of warrants			$ 2.82
Potentially dilutive securities			13,362,319	9,225,014
Restricted stock units [Member]
Potentially dilutive securities			730,994	333,500
Unrecognized compensation expense recognition period					3 years 2 months 12 days
Unrecognized compensation expense			$ 1,800,000
Compensation expense					$ 300,000
Perceptive Credit Agreement [Member]
Warrant exercise price per share			$ 3.28
Sale Agreement [Member]
Common stock issuable under agreement						50,000,000
Net proceeds			$ 41,900,000
Common stock shares sold during the period			18,080,708
Equity Incentive Plans [Member]
Unrecognized compensation expense recognition period			5 years 3 months 18 days		2 years 3 months 18 days
Description maximum number of shares reserved for grant			the Company granted Restricted Stock Units (“RSUs”) representing an aggregate of 492,744 and 341,000 shares, respectively, to certain management employees of the Company and to members of its Board of Directors. The RSUs vest annually over a period of four years for employees and semi-annually over a period of one year for directors. Total compensation expense related to unvested RSUs for the three months ended March 31, 2021 and 2020 was $0.1 million and $28,000, respectively. During the three months ended March 31, 2021, 87,750 shares vested in connection with grants of RSUs. With respect to these vested RSUs, 26,365 shares valued at approximately $59,000 were withheld by the Company to cover employees’ tax liabilities. On March 25, 2021, these shares were retired by the Company and were no longer outstanding as of March 31, 2021
Weighted average remaining contractual life of stock options outstanding					6 years 6 months
Unrecognized compensation expense			$ 5,300,000
Stock-based compensation expense					$ 2,900,000
Warrants [Member]
Potentially dilutive securities			4,528,160	2,138,160	4,528,160

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Credit facility	10.00%
Public offering description	(i) Perceptive Advisors, a principal stockholder of ADMA, purchased 4,563,700 shares of common stock through one of its affiliates, (ii) Dr. Grossman purchased 22,857 shares of common stock directly and 22,857 shares indirectly through an entity he controls, (iii) Lawrence P. Guiheen, a director of the Company, purchased 20,000 shares of common stock, (iv) Mr. Grossman purchased 28,571 shares of common stock directly and 57,143 shares indirectly through an entity he controls, (v) Brian Lenz, the Company’s Executive Vice President and Chief Financial Officer, purchased 7,142 shares of common stock, and (vi) Dr. James Mond, the Company’s Chief Scientific Officer and Chief Medical Officer, purchased 4,285 shares of common stock, all at the public offering price of $3.50 per share
Rent expense	$ 300,000	$ 100,000
Areth, LLC [Member]
Rent expense	$ 30,000	$ 30,000

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
COMMITMENT AND CONTINGENCIES
Plasma supply agreement term	10 years
Purchase of raw material	$ 12.7	$ 2.0
Purchase percentage from inventory	72.00%	46.00%

SEGMENTS (Details) - USD ($)	3 Months Ended
SEGMENTS (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Revenues	$ 16,048,618	$ 10,199,744
Cost of product revenue	17,770,122	16,829,226
Loss from operations	(15,164,249)	(16,769,786)
Interest and other expense, net	(42,001)	(6,421)
Net loss	(18,379,941)	(19,245,230)
Depreciation and amortization expense	1,229,628	788,838
TOTAL ASSETS	235,667,028		$ 207,673,394
ADMA BioManufacturing
Revenues	13,421,043	7,743,275
Cost of product revenue	15,449,757	14,451,954
Loss from operations	(9,505,689)	(12,476,144)
Interest and other expense, net	(21,513)	(238,873)
Net loss	(9,527,202)	(12,715,017)
Capital expenditure	1,012,980	1,914,614
Depreciation and amortization expense	1,009,770	674,973
TOTAL ASSETS	156,535,177	104,645,897
Plasma Collection Centers
Revenues	2,591,867	2,420,761
Cost of product revenue	2,320,365	2,377,272
Loss from operations	(1,970,841)	(457,155)
Interest and other expense, net	(384)	0
Net loss	(1,971,225)	(457,155)
Capital expenditure	1,558,181	160,262
Depreciation and amortization expense	217,991	111,289
TOTAL ASSETS	17,397,612	5,376,807
Corporate
Revenues	35,708	35,708
Cost of product revenue	0	0
Loss from operations	(3,687,719)	(3,836,487)
Interest and other expense, net	(3,193,795)	(2,236,571)
Net loss	(6,881,514)	(6,073,058)
Capital expenditure	0	0
Depreciation and amortization expense	1,867	2,576
TOTAL ASSETS	61,734,239	100,501,123
Consolidated (member)
Revenues	16,048,618	10,199,744
Cost of product revenue	17,770,122	16,829,226
Loss from operations	(15,164,249)	(16,769,786)
Interest and other expense, net	(3,215,692)	(2,475,444)
Net loss	(18,379,941)	(19,245,230)
Capital expenditure	2,571,161	2,074,876
Depreciation and amortization expense	1,229,628	788,838
TOTAL ASSETS	$ 235,667,028	$ 210,523,827

LEASE OBLIGATIONS (Details)	Mar. 31, 2021 USD ($)
LEASE OBLIGATIONS
Remainder of 2021	$ 852,315
2022	1,374,513
2023	1,386,375
2024	1,257,300
2025	1,261,052
2026	990,732
Thereafter	4,718,836
Total payments	11,841,123
Less: imputed interest	5,103,624
Current portion	317,910
Total	$ 6,419,589

LEASE OBLIGATIONS (Details Narrative) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
LEASE OBLIGATIONS
Lease and rent expense	$ 0.3	$ 0.1
Operating Lease liabilities	$ 6.7	4.7
Weighted average remaining term	9 years 3 months 18 days
Right to use assets and corresponding lease liabilities	$ 2.1
Incremental borrowing rate	13.00%
Cash payments for lease	$ 0.2	$ 0.1

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$ 2,751,956	$ 2,017,866
Noncash Financing and Inesting Activities:
Equipment acquired reflected in accounts payable and accrued liabilities	1,797,249	2,340,337
Right-to-use assets in exchange for lease obligations	$ 2,073,627	$ 545,630

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Feb. 11, 2020	May 07, 2021	Feb. 21, 2020	Mar. 31, 2021	Mar. 31, 2020
Proceeds from issuance of common stock	$ 82,300,000		$ 12,300,000	$ 41,912,515	$ 88,704,039
Sale Agreement [Member]
Common stock shares sold during the period				18,080,708
Jefferies LLC [Member] \| Sale Agreement [Member] \| Subsequent Event [Member]
Proceeds from issuance of common stock		$ 10,900,000
Remaining gross balance that can be raised		$ 7,900,000
Common stock shares sold during the period		5,144,647